Skip to results

Expected publication date

Expected publication date

Area of interest

Area of interest

Type (1 selected)

Type

Guidance programme

Showing 1 to 372 of 372

Guidance, NICE advice and quality standards in development
TitleTypeExpected publication date
Abaloparatide for treating idiopathic or hypogonadal osteoporosis in men [ID4059]Technology appraisal guidanceTBC
Abaloparatide for treating osteoporosis in postmenopausal women [ID882]Technology appraisal guidance
Abatacept for preventing moderate to severe acute graft-versus-host disease after haematopoietic stem cell transplant in people 6 years and over [ID6185]Technology appraisal guidanceTBC
Abemaciclib with abiraterone acetate and prednisone for treating hormone-relapsed metastatic prostate cancer [ID6230]Technology appraisal guidanceTBC
Abicipar pegol for treating wet age-related macular degeneration ID1533Technology appraisal guidanceTBC
Abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768]Technology appraisal guidanceTBC
Acute kidney injury: prevention, detection and management - Assessing risk factors for acute kidney injury in adults having iodine-based contrast mediaNICE guideline
Adrenal insufficiency: identification and managementNICE guideline
Alcohol-mediated perivascular renal denervation for resistant hypertensionInterventional procedures guidance
Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer [ID6368]Technology appraisal guidance
ALXN1840 for treating Wilson disease TS ID 9950Technology appraisal guidanceTBC
Alzheimer's disease (early) - gantenerumab [ID6142]Technology appraisal guidanceTBC
Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer ID5110Technology appraisal guidanceTBC
Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer ID6256Technology appraisal guidanceTBC
Amyotrophic lateral sclerosis - SAR443820 [ID6386]Technology appraisal guidanceTBC
Andexanet alfa for reversing anticoagulation in people with intracranial haemorrhage (part review of TA697) [ID6335]Technology appraisal guidance
Anhydrous sodium thiosulfate (Pedmarqsi) for preventing ototoxicity caused by cisplatin chemotherapy in people aged 1 month to 17 years with localised solid tumours [ID1001]Technology appraisal guidanceTBC
Apalutamide with gonadotrophin-releasing hormone agonist and radiotherapy for treating high-risk, localised or locally advanced prostate cancer [ID6215]Technology appraisal guidanceTBC
Arimoclomol for treating Niemann-Pick disease Type C [ID1312]Highly specialised technologyTBC
Artificial intelligence (AI) technologies for assessing skin lesions referred on the urgent suspected cancer pathwayHealth technology evaluationTBC
Artificial intelligence software to help detect fractures in the emergency department (provisional title)Health technology evaluation
Asthma: diagnosis, monitoring and chronic asthma managementNICE guidelineTBC
Asunercept for treating glioblastoma [1301]Technology appraisal guidanceTBC
Atezolizumab (Tecentriq) + bevacizumab (Avastin) + chemotherapy for ovarian cancer TS ID 10701Technology appraisal guidanceTBC
Atezolizumab for adjuvant treatment of renal cell carcinoma with a high risk of metastasis [ID5101]Technology appraisal guidanceTBC
Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]Technology appraisal guidanceTBC
Atezolizumab for untreated advanced or recurrent non-small cell lung cancer when platinum-doublet chemotherapy is unsuitable [ID6218]Technology appraisal guidanceTBC
Atezolizumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6148]Technology appraisal guidanceTBC
Atezolizumab with cabozantinib for treating metastatic non-small-cell lung cancer after platinum-based chemotherapy and 1 PD-L1 checkpoint inhibitor [ID6213]Technology appraisal guidanceTBC
Aumolertinib for untreated EGFR mutation-positive non-small-cell lung cancer [ID4000]Technology appraisal guidanceTBC
Autologous anti-CD19-transduced CD3+ cells for treating relapsed or refractory mantle cell lymphoma [ID6325]Technology appraisal guidance
Autologous chondrocyte implantation using 3D collagen matrix (novocart 3D) for treating articular cartilage defects of the knee [ID2707]Technology appraisal guidanceTBC
Avapritinib for treating advanced systemic mastocytosis ID3770Technology appraisal guidanceTBC
Avelumab for previously treated platinum-resistant ovarian cancer ID1497Technology appraisal guidanceTBC
Avelumab for untreated PD-L1 positive recurrent or metastatic non-small-cell lung cancer [ID1261]Technology appraisal guidanceTBC
Baricitinib for treating juvenile idiopathic arthritis in children and young people aged 1 to 17 [ID6143]Technology appraisal guidanceTBC
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 2 therapies [ID5108]Technology appraisal guidanceTBC
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 4 or more therapies [ID2701]Technology appraisal guidanceTBC
Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6212Technology appraisal guidance
Belantamab mafodotin with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6211Technology appraisal guidanceTBC
Belzutifan for previously treated advanced renal cell carcinoma [ID6154]Technology appraisal guidanceTBC
Belzutifan for treating tumours associated with von Hippel-Lindau disease [ID3932]Technology appraisal guidanceTBC
Benralizumab for treating eosinophilic oesophagitis in people aged 12 to 65 [ID5093]Technology appraisal guidanceTBC
Bevacizumab in combination with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer [ID1145]Technology appraisal guidance
Bimatoprost implant for treating open angle glaucoma or ocular hypertension in people who are unsuitable for topical treatments [ID6180]Technology appraisal guidanceTBC
Bimekizumab for treating moderate to severe hidradenitis suppurativa [ID6134]Technology appraisal guidance
Bipolar disorder: assessment and management (extraordinary review)NICE guidelineTBC
Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease ID6405Health technology evaluationTBC
Botulinum toxin type A for treating upper or lower limb focal spasticity associated with stroke [ID768]Technology appraisal guidanceTBC
Breast cancer guidelinesNICE guidelineTBC
Brentuximab vedotin with doxorubicin, dacarbazine and vinblastine for previously untreated late-stage classical Hodgkin lymphoma (including Review of TA594) [ID6334]Technology appraisal guidance
Burosumab for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia [ID3924 ]Technology appraisal guidanceTBC
Burosumab for treating X-linked hypophosphataemia in adults [ID3822]Technology appraisal guidanceTBC
Cabotegravir for preventing HIV-1 in adults and young people [ID6255]Technology appraisal guidance
Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243]Technology appraisal guidance
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]Technology appraisal guidanceTBC
Canakinumab for adjuvant treatment of resectable or resected stage 2A to 3B non-small-cell lung cancer [ID5114]Technology appraisal guidanceTBC
Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment [ID6370]Technology appraisal guidance
Cardiometabolic disease prevention and treatment guidelinesNICE guidelineTBC
Cediranib with olaparib for treating recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer after 3 therapies [ID1639]Technology appraisal guidanceTBC
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer [ID3949]Technology appraisal guidanceTBC
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (review of HST12) [ID6145]Technology appraisal guidance
Chronic heart failure in adults: diagnosis and management - Pharmacological treatment of chronic heart failureNICE guidelineTBC
Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies [ID4012]Technology appraisal guidanceTBC
Cimavax for treating wild-type EGFR-positive non-small-cell lung cancer [1259]Technology appraisal guidanceTBC
Cladribine for treating relapsing multiple sclerosis ID6263Technology appraisal guidance
Cobolimab with dostarlimab and docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [ID6398]Technology appraisal guidanceTBC
COLOFIT algorithm to guide colorectal cancer pathway referral in primary care: early value assessmentHealth technology evaluationTBC
Colon cancer (adjuvant) - irinotecan [ID379]Technology appraisal guidanceTBC
Cositecan for treating platinum or taxane resistant advanced, mucinous, epithelial ovarian cancer [ID826]Technology appraisal guidanceTBC
Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (MA review of TA529) [ID6289]Technology appraisal guidance
Crovalimab for treating paroxysmal nocturnal haemoglobinuria [ID6140]Technology appraisal guidance
CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attackDiagnostics guidance
Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over [ID5104]Technology appraisal guidance
Danicopan as an add-on treatment to a C5 inhibitor for treating extravascular haemolysis in adults with paroxysmal nocturnal haemoglobinuria [ID5088]Technology appraisal guidance
Dapagliflozin for treating chronic kidney disease [ID6411]Technology appraisal guidance
Daprodustat for treating anaemia in people with chronic kidney disease [ID3987]Technology appraisal guidanceTBC
Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when high-dose chemotherapy with stem cell transplant is unsuitable [ID3843]Technology appraisal guidanceTBC
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297Technology appraisal guidanceTBC
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297Technology appraisal guidance
Datopotamab deruxtecan for previously treated hormone receptor-positive HER2-negative unresectable or metastatic breast cancer [ID6348]Technology appraisal guidanceTBC
DCVax-L for treating glioblastoma [ID836]Technology appraisal guidanceTBC
Delandistrogene moxeparvovec for treating Duchenne muscular dystrophy in children 4 to 7 years ID 3897Technology appraisal guidanceTBC
Diabetic retinopathyNICE guidelineTBC
Diabetic retinopathy - ruboxistaurin [ID382]Technology appraisal guidanceTBC
Digital supported self-management technologies for adults with chronic obstructive pulmonary disease: early value assessmentHealth technology evaluation
Digitally enabled therapy for chronic tic disorders and Tourette SyndromeMedical technologies guidance
Direct skeletal fixation of limb or digit prostheses using intraosseous transcutaneous implantsInterventional procedures guidance
Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]Technology appraisal guidance
Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314]Technology appraisal guidanceTBC
Drug eluting stents for treating coronary heart disease: late stage assessmentHealth technology evaluationTBC
Dupilumab for treating chronic spontaneous urticaria in people 12 years and over [ID4055]Technology appraisal guidanceTBC
Dupilumab for treating moderate to severe chronic obstructive pulmonary disease ID6235Technology appraisal guidanceTBC
Durvalumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID6220]Technology appraisal guidanceTBC
Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]NICE guidelineTBC
Durvalumab for untreated unresectable hepatocellular carcinoma [ID4068]Technology appraisal guidanceTBC
Durvalumab with concurrent chemoradiation for treating unresectable locally advanced non-small-cell lung cancer [ID3906]Technology appraisal guidanceTBC
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for untreated advanced or recurrent endometrial cancer ID6317Technology appraisal guidanceTBC
Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma ID2725Technology appraisal guidanceTBC
Duvelisib for treating relapsed or refractory peripheral T-cell lymphoma [ID5076]Technology appraisal guidanceTBC
Early and locally advanced breast cancer: diagnosis and management - Neoadjuvant chemotherapy and ovarian function suppression (update)NICE guideline
Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A [ID6170]Technology appraisal guidanceTBC
Efgartigimod for treating generalised myasthenia gravis [ID4003]Technology appraisal guidanceTBC
Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060]Technology appraisal guidanceTBC
Elacestrant for treating oestrogen receptor-positive, HER2-negative advanced breast cancer with an ESR1 mutation after at least 1 endocrine treatment [ID6225]Technology appraisal guidanceTBC
Elafibranor for treating primary biliary cholangitis [ID6331]Technology appraisal guidanceTBC
Elranatamab for treating relapsed or refractory multiple myeloma after 3 therapies [ID4026]Technology appraisal guidance
Empagliflozin for preventing cardiovascular events after acute myocardial infarction ID6240Technology appraisal guidanceTBC
Endometriosis: diagnosis and management - diagnosing endometriosisNICE guideline
Endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cholangiocarcinoma or pancreatic adenocarcinomaInterventional procedures guidanceTBC
Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies [ID3845]Technology appraisal guidance
Epilepsies in children, young people and adults (extraordinary review)NICE guidelineTBC
Eplontersen for treating polyneuropathy caused by hereditary transthyretin amyloidosis [ID6337]Technology appraisal guidance
ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623]Technology appraisal guidanceTBC
Erdafitinib for previously treated FGFR-positive advanced solid tumours in people aged 6 and over [ID4058]Technology appraisal guidanceTBC
Erdafitinib for treating metastatic or unresectable FGFR-altered urothelial cancer [ID1333]Technology appraisal guidance
Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B [ID3812]Technology appraisal guidanceTBC
Evinacumab for treating homozygous familial hypercholesterolaemia in people aged 12 years and over [ID2704]Technology appraisal guidance
Evobrutinib for treating relapsing multiple sclerosis [ID6313]Technology appraisal guidanceTBC
Exagamglogene autotemcel for treating sickle cell disease [ID4016]Technology appraisal guidance
Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia [ID4015]Technology appraisal guidanceTBC
Exploratory economic modelling of SARS-CoV-2 viral detection point of care tests and serology testsDiagnostics guidanceTBC
Falls: assessment and prevention in older people and people 50 and over at higher risk (update)NICE guideline
Faricimab for treating macular oedema caused by retinal vein occlusion [ID6197]Technology appraisal guidance
Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (Review of TA756) [ID5115]Technology appraisal guidance
Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over [ID1651]Technology appraisal guidance
Fertility problems: assessment and treatmentNICE guideline
Fezolinetant for treating vasomotor symptoms associated with the menopause [ID5071]Technology appraisal guidanceTBC
Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032]Technology appraisal guidance
Filgotinib for treating moderately to severely active Crohn's disease [ID6236]Technology appraisal guidanceTBC
Fosdenopterin for treating molybdenum cofactor deficiency type A [ID6264]Highly specialised technology
Fruquintinib for previously treated metastatic colorectal cancer ID6274Technology appraisal guidance
Futibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement [ID6302]Technology appraisal guidance
Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over [ID3988]Technology appraisal guidance
GID-MT567 Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic painMedical technologies guidanceTBC
Gilteritinib for maintenance treatment of FLT3-mutation-positive acute myeloid leukaemia after stem cell transplant [ID6243]Technology appraisal guidanceTBC
Givinostat for treating Duchenne muscular dystrophy in people 6 years and over ID6323Technology appraisal guidanceTBC
Glaucoma - lerdelimumab (CAT-152) [ID383]Technology appraisal guidanceTBC
Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse B-cell lymphoma ID6202Technology appraisal guidanceTBC
Guselkumab for previously treated moderately to severely active Crohn's disease ID6238Technology appraisal guidanceTBC
Guselkumab for treating moderately to severely active ulcerative colitis ID6237Technology appraisal guidanceTBC
Harmful gambling: identification, assessment and managementNICE guideline
Heart failure algorithms for remote monitoring in people with cardiac implantable electronic deviceDiagnostics guidance
Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627]Technology appraisal guidanceTBC
Hydromethylthionine mesylate for treating mild cognitive impairment or mild or moderate dementia caused by Alzheimer's disease ID6343Technology appraisal guidanceTBC
Ibrutinib for treating relapsed or refractory follicular lymphoma [1251]Technology appraisal guidanceTBC
Ibrutinib for treating relapsed or refractory follicular lymphoma and marginal zone lymphoma [ID1251]Technology appraisal guidanceTBC
Ibrutinib for untreated mantle cell lymphoma [ID1221]Technology appraisal guidanceTBC
Idebenone for treating visual impairment in Leber's hereditary optic neuropathy in people 12 years and over [ID547]Technology appraisal guidanceTBC
Imetelstat for treating relapsed or refractory transfusion-dependent myelodysplastic syndromes [ID3922]Technology appraisal guidanceTBC
Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy ID6373Technology appraisal guidanceTBC
Implanting a baroreceptor stimulation device for resistant hypertensionInterventional procedures guidanceTBC
Infigratinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement [ID3992]Technology appraisal guidanceTBC
Insertion of neo-chordae into the beating heart for mitral regurgitationInterventional procedures guidanceTBC
Iodine (131I)–apamistamab for treating relapsed or refractory acute myeloid leukaemia before an allogeneic haematopoietic stem cell transplant [ID6355]Technology appraisal guidanceTBC
Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]Technology appraisal guidanceTBC
Iptacopan for treating paroxysmal nocturnal haemoglobinuria [ID6176]Technology appraisal guidance
Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [Review of TA658] [ID4067]Technology appraisal guidance
Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis [ID3834]Technology appraisal guidanceTBC
Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation [ID6198]Technology appraisal guidance
Ixazomib citrate for maintenance treatment of untreated multiple myeloma in people who cannot have autologous stem cell transplant [ID2706]Technology appraisal guidanceTBC
Kidney CancerNICE guidelineTBC
KTE-X19 for previously treated B-precursor acute lymphoblastic leukaemia in people aged 2 to 21 [ID1336]Technology appraisal guidanceTBC
Lacosamide for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [ID1687]Technology appraisal guidanceTBC
Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over [ID4025]Technology appraisal guidanceTBC
Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID4043]Technology appraisal guidanceTBC
Lenadogene nolparvovec for treating Leber's hereditary optic neuropathy caused by the G11778A ND4 mitochondrial mutation [ID1410]Technology appraisal guidanceTBC
Leniolisib for activated phosphoinositide 3-kinase delta syndrome in people 12 years and over [ID6130]Highly specialised technology
Lenvatinib with pembrolizumab for untreated recurrent or advanced endometrial cancer [ID3966]Technology appraisal guidanceTBC
Leriglitazone for treating andrenoleukodystrophy [ID3903]Technology appraisal guidanceTBC
Letermovir for preventing cytomegalovirus infection after a kidney transplant [ID6166]Technology appraisal guidanceTBC
Linzagolix for treating moderate to severe symptoms of uterine fibroids [ID6190]Technology appraisal guidanceTBC
Linzagolix for treating pain caused by endometriosis [ID6357]Technology appraisal guidanceTBC
Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma [ID1444]Technology appraisal guidanceTBC
Lisocabtagene maraleucel for treating relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6174]Technology appraisal guidanceTBC
Lisocabtagene maraleucel for treating relapsed or refractory diffuse large B-cell lymphoma, high grade B-cell lymphoma, primary mediastinal large B-cell lymphoma or follicular lymphoma grade 3B after first-line chemotherapy [ID3887]Technology appraisal guidance
LN-145 for treating recurrent, persistent or metastatic cervical cancer [ID3844]Technology appraisal guidanceTBC
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (in combination with bevacizumab) [ID44]Technology appraisal guidanceTBC
Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43]Technology appraisal guidanceTBC
Lurbinectedin for treating advanced platinum-resistant ovarian cancer ID1340Technology appraisal guidanceTBC
Lurbinectedin for treating advanced small-cell lung cancer on or after platinum-based chemotherapy [ID3872]Technology appraisal guidanceTBC
Lymphoedema: prevention and management in people with early, locally advanced, and advanced breast cancer (update)NICE guidelineTBC
Managing common infections - antimicrobial prescribing guidelinesNICE guidelineTBC
Maralixibat for treating cholestatic pruritus in Alagille syndrome [ID3941]Technology appraisal guidanceTBC
Maralixibat for treating progressive familial intrahepatic cholestasis [ID3818]Technology appraisal guidanceTBC
Maribavir for cytomegalovirus infection after haematopoietic stem cell transplant [ID5075]Technology appraisal guidanceTBC
Marstacimab for treating severe haemophilia A or severe haemophilia B in people 12 years and over [ID6342]Technology appraisal guidanceTBC
Masitinib with riluzole for treating amyotrophic lateral sclerosis ID6257Technology appraisal guidanceTBC
Maternal and child nutritionNICE guideline
Melanoma (metastatic) - talimogene laherparepvec [ID508]Technology appraisal guidance
Menopause: diagnosis and managementNICE guidelineTBC
Mental health guidelinesNICE guidelineTBC
Mirikizumab for treating moderately to severely active Crohn's disease ID6244Technology appraisal guidanceTBC
Mirvetuximab soravtansine for previously treated platinum-resistant FR-alpha positive ovarian cancer [ID1527]Technology appraisal guidanceTBC
Molnupiravir for treating COVID 19 [ID6340]Technology appraisal guidance
MTX110 for untreated diffuse intrinsic pontine glioma [ID2695]Technology appraisal guidanceTBC
Multiple sclerosis (relapsing, remitting, highly active) - natalizumab and Tyruko (natalizumab biosimilar) (after disease modifying therapy) [ID6369]Technology appraisal guidanceTBC
Nemolizumab for treating moderate to severe atopic dermatitis in people aged 12 and over or prurigo nodularis in adults ID6221Technology appraisal guidanceTBC
Netarsudil-latanoprost for previously treated open-angle glaucoma or ocular hypertension [ID1363]Technology appraisal guidanceTBC
Neuroendocrine tumours (metastatic, unresectable, progressive) - everolimus and sunitinib [ID858]Technology appraisal guidance
Nintedanib for treating fibrosing interstitial lung disease in people aged 6 to 17 [ID6194]Technology appraisal guidanceTBC
Nivolumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID6310]Technology appraisal guidanceTBC
Nivolumab for adjuvant treatment of completely resected melanoma at high risk of recurrence in people aged 12 and over [ID6189]Technology appraisal guidanceTBC
Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]Technology appraisal guidance
Nivolumab for adjuvant treatment of localised renal cell carcinoma [ID6362]Technology appraisal guidanceTBC
Nivolumab for adjuvant treatment of resected non-small-cell lung cancer [ID4053]Technology appraisal guidanceTBC
Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer [ID5102]Technology appraisal guidanceTBC
Nivolumab with docetaxel for treating hormone-relapsed advanced prostate cancer after 1 or 2 hormonal therapies [ID4048]Technology appraisal guidanceTBC
Nivolumab with ipilimumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136]Technology appraisal guidanceTBC
Nivolumab with ipilimumab for untreated unresectable metastatic oesophageal squamous cell carcinoma ID1629Technology appraisal guidanceTBC
Nivolumab with ipilimumab for untreated unresectable or metastatic urothelial cancer when cisplatin is unsuitable [ID3939]Technology appraisal guidanceTBC
Nivolumab with ipilimumab for untreated unresectable stage 3 non-small-cell lung cancer [ID6248]Technology appraisal guidanceTBC
Non-invasive skin closure devices for surgical incisions (MT775)Medical technologies guidanceTBC
Novel home-testing devices for diagnosing obstructive sleep apnoea/hypopnoea syndromeDiagnostics guidance
Nusinersen and risdiplam for treating spinal muscular atrophy (review of TA588 and TA755) [ID6195]Technology appraisal guidance
NY-ESO-1 T-cells for treating synovial sarcoma ID1286Technology appraisal guidanceTBC
Obeticholic acid for treating liver fibrosis in people with steatohepatitis [ID1645]Technology appraisal guidanceTBC
Odevixibat for treating cholestasis and pruritus in Alagille Syndrome [ID6181]Technology appraisal guidanceTBC
Olaparib for maintenance treatment of BRCA-negative platinum-sensitive relapsed ovarian, fallopian tube or primary peritoneal cancer [ID6205]Technology appraisal guidanceTBC
Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (Review of TA762) [ID6336]Technology appraisal guidance
Olaparib with cediranib for treating platinum-resistant recurrent ovarian cancer after 1 or 2 therapies [ID4065]Technology appraisal guidanceTBC
Olipudase alfa for treating Niemann-Pick disease types A and B [ID3913 ]Highly specialised technologyTBC
Omburtamab for treating relapsed neuroblastoma [ID1664]Technology appraisal guidanceTBC
One-piece closed bags for adults with a colostomy: Late Stage AssessmentHealth technology evaluationTBC
ONS-5010 for treating wet age-related macular degeneration ID6320Technology appraisal guidanceTBC
Optical Coherence Tomography to guide percutaneous coronary interventionInterventional procedures guidanceTBC
Oral paclitaxel with encequidar for treating advanced breast cancer [ID5111]Technology appraisal guidanceTBC
OrganOx metra for liver transplant [ID5116]Technology appraisal guidanceTBC
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (Review of TA761) [ID5120]Technology appraisal guidance
Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6328]Technology appraisal guidanceTBC
Osteoporosis: risk assessment, treatment, and fragility fracture prevention (update)NICE guidelineTBC
Otilimab for treating moderate to severe rheumatoid arthritis [ID6171]Technology appraisal guidanceTBC
Overweight and obesity managementNICE guidelineTBC
Oxybutynin hydrochloride for managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida [ID5089]Technology appraisal guidanceTBC
Palforzia for treating peanut allergy in children aged 1 to 3 [ID6144]Technology appraisal guidanceTBC
Palopegteriparatide for treating chronic hypoparathyroidism ID6380Technology appraisal guidanceTBC
Palovarotene for preventing heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID3739]Highly specialised technologyTBC
Palovarotene for treating flare ups of heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID2721]Highly specialised technologyTBC
Parsaclisib for treating relapsed or refractory marginal zone lymphoma [ID3976]Technology appraisal guidanceTBC
Peezy Midstream for urine collection (MT446)Medical technologies guidanceTBC
Pegcetacoplan for amyotrophic lateral sclerosis TS ID 10594Technology appraisal guidanceTBC
Pegcetacoplan for treating geographic atrophy [ID4041]Technology appraisal guidanceTBC
Pegzilarginase for treating arginase-1 deficiency [ID4029]Highly specialised technology
Pembrolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID5094]Technology appraisal guidance
Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer [ID3907]Technology appraisal guidance
Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138]Technology appraisal guidanceTBC
Pembrolizumab with chemotherapy and surgery for treating resectable gastric or gastro-oesophageal junction cancer [ID2696]Technology appraisal guidanceTBC
Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent ID6207Technology appraisal guidanceTBC
Pembrolizumab with chemotherapy for treating HER2-negative advanced gastric or gastro-oesophageal junction adenocarcinoma [ID4030]Technology appraisal guidance
Pembrolizumab with chemotherapy for treating platinum-resistant recurrent ovarian cancer after 1 or 2 treatments [ID6363]Technology appraisal guidanceTBC
Pembrolizumab with enfortumab vedotin for untreated metastatic urothelial cancer ID6332Technology appraisal guidanceTBC
Pembrolizumab with enzalutamide for treating metastatic hormone-relapsed prostate cancer [ID5103]Technology appraisal guidanceTBC
Pembrolizumab with ipilimumab for treating PD-L1-positive advanced non-small-cell lung cancer [ID3861]Technology appraisal guidanceTBC
Pembrolizumab with lenvatinib for previously treated metastatic colorectal cancer [ID5112]Technology appraisal guidanceTBC
Pembrolizumab with lenvatinib for treating EGFR, ALK or ROS1-negative metastatic non-small-cell lung cancer after a PD-1 or PD-L1 inhibitor and platinum-based chemotherapy [ID5109]Technology appraisal guidanceTBC
Pembrolizumab with lenvatinib for untreated advanced melanoma [ID3948]Technology appraisal guidanceTBC
Pembrolizumab with lenvatinib for untreated PD-L1 positive recurrent or metastatic squamous cell head and neck cancer [ID5118]Technology appraisal guidanceTBC
Pembrolizumab with olaparib for maintenance treatment of advanced squamous non-small-cell lung cancer [ID4006]Technology appraisal guidanceTBC
Pembrolizumab with olaparib for maintenance treatment of non-squamous metastatic non-small-cell lung cancer after pembrolizumab with platinum-based chemotherapy [ID4028]Technology appraisal guidanceTBC
Pembrolizumab with olaparib for treating hormone-relapsed metastatic prostate cancer after abiraterone or enzalutamide and chemotherapy [ID3814]Technology appraisal guidanceTBC
Pembrolizumab with pemetrexed and platinum-based chemotherapy for previously TKI-treated EGFR-positive metastatic non-squamous non-small-cell lung cancer [ID3873]Technology appraisal guidanceTBC
Pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated unresectable advanced malignant pleural mesothelioma ID4044Technology appraisal guidanceTBC
Pembrolizumab with platinum chemotherapy, pemetrexed and lenvatinib for untreated advanced non-squamous non-small-cell lung cancer [ID3985]Technology appraisal guidanceTBC
Pembrolizumab with platinum-based chemotherapy then pembrolizumab maintenance for treating advanced or recurrent endometrial cancer ID6381Technology appraisal guidanceTBC
Pembrolizumab with trastuzumab and chemotherapy for untreated HER2-positive advanced gastric or gastro-oesophageal junction cancer [ID3742]Technology appraisal guidanceTBC
Pembrolizumab–vibostolimab with etoposide and platinum-based chemotherapy for untreated extensive-stage small-cell lung cancer [ID6361]Technology appraisal guidanceTBC
Pemigatinib for treating myeloid or lymphoid neoplasms with a FGFR1 rearrangement [ID6172]Technology appraisal guidanceTBC
Pertuzumab–trastuzumab with chemotherapy for treating HER2-positive breast cancer [ID2724]Technology appraisal guidanceTBC
PillCam COLON 2 for investigation of the colon through direct visualisationDiagnostics guidanceTBC
Pirtobrutinib for treating chronic lymphocytic leukaemia or small lymphocytic lymphoma after 1 or more BTK inhibitors [ID6269]Technology appraisal guidanceTBC
Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma [ID3975]Technology appraisal guidanceTBC
Pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6397]Technology appraisal guidanceTBC
Pitolisant for treating narcolepsy in children and young people 6 to 17 years ID6353Technology appraisal guidanceTBC
Pneumonia: diagnosis and management (update)NICE guidelineTBC
Port Delivery System with ranibizumab for treating wet age-related macular degeneration [ID3983]Technology appraisal guidanceTBC
Pralsetinib for thyroid cancer [ID4018]Technology appraisal guidanceTBC
Quizartinib for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia [ID4042]Technology appraisal guidance
Regorafenib for treating advanced gastrointestinal stromal tumours [ID1056]Technology appraisal guidance
Rehabilitation for chronic neurological disorders including acquired brain injuryNICE guideline
Relugolix for treating hormone-sensitive prostate cancer [ID6187]Technology appraisal guidanceTBC
Relugolix–estradiol–norethisterone acetate for treating pain associated with endometriosis [ID3982]Technology appraisal guidanceTBC
Renal cell carcinoma Pathways Pilot [ID6186]Technology appraisal guidanceTBC
Ribociclib in combination with endocrine therapy and goserelin for previously untreated hormone receptor-positive, HER2-negative advanced breast cancer in premenopausal women (ID1307)Technology appraisal guidanceTBC
Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive, HER2-negative early breast cancer [ID6153]Technology appraisal guidanceTBC
Risankizumab for previously treated moderately to severely active ulcerative colitis in people aged 16 and over ID6209Technology appraisal guidanceTBC
Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]Technology appraisal guidanceTBC
Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]Technology appraisal guidanceTBC
Robot-assisted surgery for orthopaedic procedures: early value assessmentHealth technology evaluationTBC
Robot-assisted surgery for soft-tissue procedures: early value assessmentHealth technology evaluation
Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly [ID1596]Technology appraisal guidanceTBC
Rozanolixizumab for treating antibody-positive generalised myasthenia gravis [ID5092]Technology appraisal guidanceTBC
Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy [ID5100]Technology appraisal guidance
Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (Review of TA611) [ID4069]Technology appraisal guidance
Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids in people aged 12 and over [ID6377]Technology appraisal guidanceTBC
Ruxolitinib for treating moderate to severe chronic graft-versus-host disease after an allogeneic stem cell transplant in people 28 days to 17 years [ID6427]Technology appraisal guidanceTBC
Ruxolitinib for treating non-segmental vitiligo in people 12 years and over [ID3998]Technology appraisal guidance
Sacituzumab govitecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor [ID6375]Technology appraisal guidanceTBC
Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more therapies [ID4033]Technology appraisal guidanceTBC
Sacral nerve stimulation for idiopathic chronic non-obstructive urinary retentionInterventional procedures guidanceTBC
Secukinumab for treating enthesitis-related arthritis or juvenile psoriatic arthritis [ID3738]Technology appraisal guidanceTBC
Selective internal radiation therapy with QuiremSpheres for treating unresectable advanced hepatocellular carcinoma (Partial review of TA688) [ID6376]Technology appraisal guidance
Selpercatinib for advanced thyroid cancer with RET alterations that has not been treated with systemic therapy [ID6132]Technology appraisal guidance
Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (MA review of TA760) [ID6293]Technology appraisal guidance
Selpercatinib for untreated RET-positive advanced thyroid cancer [ID6183]Technology appraisal guidanceTBC
Sipavibart for preventing COVID 19 [ID6282]Technology appraisal guidance
Sodium phenylbutyrate–ursodoxicoltaurine for treating amyotrophic lateral sclerosis [ID6246]Technology appraisal guidanceTBC
Somapacitan for treating growth hormone deficiency in children [ID6178]Technology appraisal guidanceTBC
Sotatercept for treating pulmonary arterial hypertension [ID6163]Technology appraisal guidanceTBC
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (MA review of TA781) [ID6287]Technology appraisal guidance
SpaceOAR hydrogel spacer for reducing rectal toxicity during radiotherapy for prostate cancer (Suspended – referred to technology appraisals)Medical technologies guidanceTBC
Sparsentan for treating primary IgA nephropathy [ID6308]Technology appraisal guidance
Spartalizumab with dabrafenib and trametinib for untreated BRAF V600 mutation-positive unresectable or metastatic melanoma [ID1668]Technology appraisal guidance
Spesolimab for preventing generalised pustular psoriasis flares [ID6216]Technology appraisal guidanceTBC
Spesolimab for treating acute generalised pustular psoriasis [ID3963]Technology appraisal guidanceTBC
SQ HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (review of TA834) [ID6280]Technology appraisal guidance
Sugemalimab with chemotherapy for untreated metastatic non-small-cell lung cancer [ID4001]Technology appraisal guidanceTBC
Surgical correction of hallux valgus using minimal access techniquesInterventional procedures guidance
Surgical vessel sealing systems (MT798)Medical technologies guidanceTBC
Suspected sepsis: recognition, diagnosis and early managementNICE guidelineTBC
Suspected sepsis: recognition, diagnosis and early managementNICE guideline
Tafamidis for treating transthyretin amyloidosis with cardiomyopathy [ID6327]Technology appraisal guidance
Talacotuzumab for untreated acute myeloid leukaemia [ID1262]Technology appraisal guidanceTBC
Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer [ID4004]Technology appraisal guidanceTBC
Tarlatamab for previously treated advanced small-cell lung cancer [ID6364]Technology appraisal guidance
Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401Technology appraisal guidanceTBC
Tebentafusp for treating advanced (unresectable or metastatic) uveal melanoma [ID1441]Technology appraisal guidanceTBC
Technologies for the assessment of attention deficit hyperactivity disorder (ADHD)Diagnostics guidanceTBC
Teclistamab for treating relapsed or refractory multiple myeloma after 3 treatments (Review of TA869) [ID6333]Technology appraisal guidance
Telisotuzumab vedotin for treating c-MET overexpressed, EGFR wild-type, non-squamous advanced non-small-cell lung cancer after 1 or more systemic treatments [ID6253]Technology appraisal guidanceTBC
Tenecteplase for treating acute ischaemic stroke [ID6306]Technology appraisal guidanceTBC
Third molars (impacted) - prophylactic removal [ID898]Technology appraisal guidanceTBC
Tirzepatide for managing overweight and obesity [ID6179]Technology appraisal guidance
Tislelizumab for previously treated advanced oesophageal squamous cell cancer [ID4070]Technology appraisal guidanceTBC
Tislelizumab for treating advanced non-small-cell lung cancer after platinum-based chemotherapy [ID6161]Technology appraisal guidanceTBC
Tislelizumab in combination for untreated advanced non-small-cell lung cancer [ID6162]Technology appraisal guidanceTBC
Tisotumab vedotin for treating recurrent or metastatic cervical cancer after systemic therapy [ID3753]Technology appraisal guidanceTBC
Topical Antimicrobial dressings for wound care: Late stage assessmentHealth technology evaluationTBC
Topical rapamycin for treating facial angiofibromas associated with tuberous sclerosis complex in people 6 years and over [ID6391]Technology appraisal guidanceTBC
Total hip arthroplasty using the superpath approach for osteoarthritisInterventional procedures guidanceTBC
Tralokinumab for treating moderate to severe atopic dermatitis [ID3734]Technology appraisal guidanceTBC
Transcatheter heart valves for transcatheter aortic valve implantation in people with aortic stenosis: Late stage assessmentHealth technology evaluationTBC
Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy [ID3935]Technology appraisal guidanceTBC
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [ID6309]Technology appraisal guidance
Treatments for non-small-cell lung cancer [ID6234]Technology appraisal guidanceTBC
Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments [ID6298]Technology appraisal guidance
Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [ID6165]Technology appraisal guidanceTBC
Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227]Technology appraisal guidance
Tusamitamab ravtansine for previously treated CEACAM5-positive metastatic non-squamous non-small-cell lung cancer [ID4061]Technology appraisal guidanceTBC
Type 2 diabetes in adults: management (medicines update)NICE guideline
Ublituximab for treating relapsing–remitting multiple sclerosis ID6350Technology appraisal guidanceTBC
Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3733]Technology appraisal guidanceTBC
Urinary Tract Infection (recurrent): antimicrobial prescribingNICE guideline
Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease [ID3821]Technology appraisal guidance
Vamorolone for treating Duchenne muscular dystrophy [ID4024]Technology appraisal guidanceTBC
Veliparib with carboplatin and paclitaxel for untreated non-squamous non-small-cell lung cancer [ID1277]Technology appraisal guidanceTBC
Venetoclax with azacitidine for untreated high-risk myelodysplastic syndromes [ID6314]Technology appraisal guidanceTBC
Venetoclax with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma ID1565Technology appraisal guidanceTBC
Venetoclax with dexamethasone for treating relapsed or refractory t(11;14)-positive multiple myeloma after lenalidomide and a proteasome inhibitor [ID4040]Technology appraisal guidanceTBC
Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia when there is no 17p deletion or TP53 mutation and FCR (fludarabine, cyclophosphamide, rituximab) or BR (bendamustine, rituximab) are suitable [ID6291]Technology appraisal guidanceTBC
Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment [ID6360]Technology appraisal guidanceTBC
Vibegron for treating symptoms of overactive bladder ID6300Technology appraisal guidanceTBC
Vocimagene amiretrorepvec with extended-release 5-fluorocytosine for treating recurrent high-grade glioma [ID1425]Technology appraisal guidanceTBC
Voxelotor for treating sickle cell disease [ID1403]Technology appraisal guidance
VTS-270 for treating Niemann-Pick type C1 [ID1267]Highly specialised technologyTBC
Waldenstrom's macroglobulinaemia - ibrutinib [ID884]Technology appraisal guidance
Women's and reproductive health guidelinesNICE guidelineTBC
Zanubrutinib for treating relapsed or refractory mantle cell lymphoma after 1 or more treatments [ID6392]Technology appraisal guidanceTBC
Zanubrutinib for treating relapsed or refractory marginal zone lymphoma [ID5085]Technology appraisal guidance
Zanubrutinib for untreated chronic lymphocytic leukaemia [ID5079]Technology appraisal guidanceTBC
Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008]Technology appraisal guidance
Zio XT for detecting cardiac arrhythmiasMedical technologies guidanceTBC
Zolbetuximab with chemotherapy for untreated claudin 18.2-positive HER2 negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma [ID5123]Technology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All